您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Prasugrel
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Prasugrel
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Prasugrel图片
CAS NO:150322-43-3
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
5mg电议
100mg电议

产品介绍
Prasugrel (PCR 4099) 是一种噻吩并吡啶和前药,可抑制血小板功能。
Cas No.150322-43-3
别名普拉格雷; PCR 4099
化学名[5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate
Canonical SMILESCC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
分子式C20H20FNO3S
分子量373.44
溶解度≥ 6.22mg/mL in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Prasugrel (PCR 4099) is a platelet inhibitor with IC50 value of 1.8 μM.

Prasugrel (PCR 4099) is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI. Prasugrel (PCR 4099) reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, Prasugrel (PCR 4099) AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an ICIC50 value of 1.8 μm. From Wikipedia

References:
[1]. Pharmacokinetic basis of the antiplatelet action of prasugrel By Schroer, Karsten; Siller-Matula, Jolanta M.; Huber, Kurt From Fundamental & Clinical Pharmacology (2012), 26(1), 39-46.
[2]. Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in Rats By Sugidachi, Atsuhiro; Yamaguchi, Shinji; Jakubowski, Joseph A.; Ohno, Kosaku; Tomizawa, Atsuyuki; Hashimoto, Masami; Niitsu, Yoichi From Journal of Cardiovascular Pharmacology (2011), 58(3), 329-334.
[3]. Darius H.Prasugrel.Hamostaseologie. 2012 Aug 1;32(3):186-90.
[4]. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.J Am Coll Cardiol. 2012 Jul 17;60(3):193-9.
[5]. Spiel AO, Derhaschnig U, Schwameis M, Bartko J, Siller-Matula JM, Jilma B.Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.Clin Sci (Lond). 2012 Nov 1;123(10):591-600.